- We are
- Our scientific
platform & programs
- Join the
- Contact Us
At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases.
Founded in March 2013 as a result of the technology and know-how accumulated over two decades at Children’s Hospital of Philadelphia (CHOP), our investigational therapies have the potential to provide long-lasting effects, dramatically and positively changing the lives of patients with conditions where no, or only palliative, therapies exist. Greater understanding of the human genome and genetic abnormalities have allowed our scientists to tailor investigational therapies to patients suffering from very specific genetic diseases. This approach holds great promise in developing effective treatments to a host of inherited diseases. Our initial focus is on treating orphan diseases.
Headquartered in dynamic Philadelphia, we are a diverse, experienced team united in our goal to break down barriers for people and families affected by genetic diseases. As our name suggests, our investigational, one-time therapies are designed to spark healthy biology, and deliver potentially life-altering transformation for people and families affected by genetic disease. Spark is a member of the Roche Group.
Challenge the inevitability of genetic disease by discovering, developing and delivering treatments in ways unimaginable – until now.
A world where no life is limited by genetic disease.
Jennifer Flaisher is the Chief People Officer (CPO) at Spark Therapeutics, where she has responsibility for Human Resources (HR); Diversity, Equity and Inclusion; and Corporate Communications and Community Engagement, and is focused on enabling, empowering and inspiring Spark’s most important resource – its talented people.
Jennifer and her team are responsible for translating business priorities into talent, communication and engagement strategies that strengthen Spark’s competitiveness and ability to fulfill its mission to challenge the inevitability of genetic disease. To support this mission, Jennifer’s team is focused on building a strong, values-driven culture, where everyone is respected, feels a sense of belonging and can thrive, and communicating with all of Spark’s key stakeholders, including the broader community, to enable meaningful engagement with the Company.
Jennifer joined Spark in 2017 and previously served as the Head of HR, leading the team that recruited, hired and onboarded hundreds of team members to more than double the Company’s size over four-year period. During her more than 20 years in HR, Jennifer has held a number of senior-level roles at leading bio-pharmaceutical companies. Her expertise is centered in business transformations and, organizational effectiveness, change management, HR effectiveness and creating employee-centric solutions. She served as Vice President of HR for Teva Pharmaceuticals, leading the HR function for its U.S. business, and at Shire Pharmaceuticals (now part of Takeda), as the Chief of Staff to the CHRO, in addition to a number of senior-level HR Business Partner roles.
Jennifer holds a B.S. from the University of Maryland and an MBA from Villanova University. She sits on the board of Women Golfers Give Back, a non-profit focused on helping girls build resilience and confidence through golf.
As Spark Therapeutics Chief Executive Officer, Ron Philip leads a team of talented individuals working together to develop new therapies for people living with genetic diseases. Since joining Spark in 2017, he has played a key role in Spark’s rapid growth and achievements — most notably, directing the commercial launch of Spark’s first approved gene therapy, LUXTURNA® (voretigene neparvovec-rzyl).
Ron previously served as Chief Operating Officer, where he was responsible for leading product strategy development and execution for Spark’s early and late-stage pipeline assets, including the governance and proactive management necessary to bring more gene therapies to patients living with genetic diseases. He also was responsible for the other functions, including commercial development, marketing, pricing and reimbursement, government affairs, program and alliance management, commercial operations, diagnostics, market access and patient services functions.
Before becoming COO, Ron served as Spark’s Chief Commercial Officer and Senior Vice President, Head of Global Commercial.
With more than 30 years of experience across biopharma companies and management consulting, Ron has a proven track record of improving operating performance in multiple therapeutic categories and global markets. He held several senior leadership roles at Pfizer, including Regional President for Africa/Middle East, Head of Global Business Unit Strategy, Head of Business Development Search and Evaluation and Commercial Development Lead within Pfizer’s Innovative Products Business. He also worked at Wyeth Pharmaceuticals in U.S. commercial operations, with Deloitte Consulting in their strategy and operations practice, and at Merck and Co. in the manufacturing and marketing divisions.
Ron currently serves as the Trustee and Chair of the Science Committee at the Academy of Natural Sciences of Drexel University in Philadelphia and previously was an active board member of Cure Duchenne. Ron is a graduate of Drexel University.
Ron can be found on LinkedIn.
Paul Savidge serves as Chief Legal Officer at Spark® Therapeutics, where he brings more than 25 years of experience in the biopharmaceutical industry. He oversees Spark’s Legal and Compliance departments, which he has significantly contributed to building and developing during his nearly six-year tenure with the company. Paul is also a member of the Roche General Counsel’s Leadership Circle.
Paul joined Spark in 2016, and most recently served as General Counsel. He was integral in supporting the regulatory approval and launch planning for LUXTURNA®, the first FDA-approved gene therapy for an inherited disease in the United States. He also played a key role in Spark’s transition to an independent company within the Roche Group following the completion of Roche’s acquisition of Spark in late 2019, developing new governance models for the new Spark Board and other committees.
Prior to joining Spark, Paul served in the U.S. and European legal groups at Merck & Co., Inc. and in the regulatory and legal organizations at Bristol-Myers Squibb where he was Senior Vice President and Deputy General Counsel for the Global Commercialization, Research & Development and Europe groups. Paul began his law career as an associate at Morgan, Lewis & Bockius LLP.
Beyond his work at Spark, Paul plays an active role within community and cultural organizations, serving on the Boards of Directors for the Wharton Esherick Museum and the Jane Austen Society of North America. He is also a member of the Health Law Advisory Board of Drexel University’s Thomas R. Kline School of Law.
Paul holds a BSFS from Georgetown University’s School of Foreign Service, an M.B.A. from the Kellogg School of Management at Northwestern University, and a JD from Washington and Lee University School of Law.
Dr. Federico Mingozzi is the Chief Science & Technology officer at Spark Therapeutics. With more than twenty-five years’ experience in gene therapy, immunology, biochemistry and molecular biology in both industry and academic settings, he began his scientific career studying the genetic basis of bleeding disorders.
At the Children’s Hospital Philadelphia (CHOP) he conducted pioneering studies on liver gene transfer with adeno-associated virus (AAV) vectors and immunology. Federico was involved in several first-in-human clinical studies of gene therapy based on the AAV vector platform while serving as the director of translational research at CHOP’s Center for Cellular and Molecular Therapeutics. He also led studies aimed at the characterization of human immune responses to AAV vectors and the development of strategies to modulate vector immunogenicity.
He then joined the French National Institute of Health and Medical Research (INSERM) as Research Director, as well as Genethon — a leading French nonprofit R&D organization focused on gene therapy for rare diseases — as Team Leader. There, he spearheaded the development of in vivo gene therapies for inherited diseases from bench to bedside, while continuing to focus on the characterization of human immune responses to AAV vectors and the development of strategies to overcome immune responses in gene transfer.
Throughout his distinguished career, Federico has received several awards and has contributed to the field of gene therapy with more than one hundred and fifty scientific publications, including seminal findings in the field of AAV gene therapy. He is also the at-large director of the American Society of Gene and Cell Therapy (ASGCT) board of directors.
Federico received his bachelor’s degree in biology and his Ph.D. in biochemistry and molecular biology from the University of Ferrara in Italy, and his M.B.A. from Drexel University. He also served as faculty at the Pierre and Marie Curie University in Paris, France, and Universitat Autonoma in Barcelona, Spain.
Dr. Gallia Levy is the Chief Medical Officer at Spark Therapeutics and leads strategic and operational teams throughout the product development lifecycle with responsibility for setting the global development strategy for current and pipeline programs. She serves as the principal physician and resident medical expert at Spark.
Prior to joining Spark, Gallia was Vice President and Global Head of the Rare Blood Disorders Franchise in Product Development at Genentech, another member of the Roche Group, where she was responsible for the clinical development of treatments for hemophilia A and other rare blood disorders such as paroxysmal nocturnal hemoglobinuria (PNH), and atypical hemolytic uremic syndrome (aHUS). Gallia first joined Genentech in 2009, where she worked in both early and late-stage clinical development. She later moved to Portola Pharmaceuticals, where she led the clinical development program for hematology and oncology indications spanning Phases 1 to registrational trials. She eventually returned to Genentech, taking responsibility for the global clinical development program for HEMLIBRA® during which time she led the transition from Phase 1 through to global registration for adults and children with hemophilia A.
Gallia is board-certified in hematology and earned an M.D. and Ph.D. in Molecular and Cellular Biology from the University of Michigan, during which time discovered ADAMTS13, responsible for Thrombotic Thrombocytopenic Purpura (TTP). She completed her residency in internal medicine at Stanford University and a fellowship in hematology at the University of California, San Francisco. She also spent time at the Pasteur Institute during which she received an M.S. in Molecular and Cellular Biology from the University of Paris, VI and she holds a B.A. from the University of California, Berkeley.
Michael Retterath serves as Chief Business Officer at Spark Therapeutics, where he leads the development and implementation of Spark’s long-term corporate strategy, including portfolio and technology prioritization, enterprise-wide processes, long-range financial planning and the cultivation of collaborative partnerships to advance Spark programs.
Michael joins Spark Therapeutics from Bain & Company, where he served as a partner in the healthcare practice for a decade. In this role, Michael focused on corporate and business unit strategies, organizational transformations, product launches, growth strategies and new market entries. His experience spans multiple therapeutic areas, including rare disease, the central nervous system and ophthalmology across a wide range of modalities.
Prior to joining Bain in 2010, Michael was a partner at Monitor Group and head of the New York office, where he supported pharmaceutical treatment launches and growth strategies for 10 years. Before that, Michael was senior vice president at Sanofi Diagnostics Pasteur in Paris, France and a senior director at Boehringer Mannheim (now Roche) in Mannheim, Germany.
Michael earned an M.B.A. from the Institut Européen d’Administration des Affaires (INSEAD) and holds a MSc. in molecular biology and a BSc. in biochemistry from the University of Waterloo in Canada.
Blake Sprayberry is the Head of Commercial at Spark Therapeutics, where he is responsible for US commercial operations, commercial development, government affairs, and cross-functional activities related to the commercialization of gene therapies. He brings over 20 years of pharmaceutical and biotech industry experience, including strategy, commercial, and manufacturing.
Blake joined Spark in 2019 as Head of Commercial Development. During his tenure, Blake built the strong team, capabilities, and commercial processes needed to support and advance our gene therapy portfolio. He also led our LUXTURNA partnership with Novartis and the Spark/Roche collaboration effort, which leverages our integrated capabilities in the US and follows the Roche affiliate model outside of the US.
Prior to Spark, Blake served as the Oncology Strategy Lead for Pfizer where he was responsible for leading strategic planning and global projects. Earlier, he held commercial leadership roles at Wyeth and Pfizer, including three new product launches, expansion of the Hemophilia and Regenerative Medicine development portfolios, and leading the rhBMP-2 alliance with Medtronic. Additionally, Blake played a key role in the development of Wyeth’s biotech platform and strategy, and held roles in manufacturing, network strategy, and investment planning for in-line and portfolio biologics.
Blake served as a United States Marine Corps Officer in a variety of leadership and operations roles. He holds a BS in engineering from the US Naval Academy and an MBA from Cornell’s Johnson School of Management.
As Spark Therapeutics’ Chief Patient Supply Officer, Chris Stevens leads a team of dedicated professionals working together in manufacturing and technical operations, supply chain, quality and compliance to deliver transformational therapies for patients globally. Chris is also responsible for capital investments, engineering, EHS, real estate and facilities management across the enterprise.
Since joining Spark in 2017, Chris has effectively led teams in several key areas, initially serving as Head of Manufacturing where he led the development of Spark’s manufacturing network through the filing and launch of Luxturna, the first approved gene therapy for genetic disease in both the US and EU. Later, Chris held the role of Asset General Manager, Hemophilia A where he had end to end responsibility for Spark’s Hem A program before being promoted to Head of Product Strategy where he led the team responsible for all programs in Spark’s portfolio. Chris was appointed Chief Patient Supply Officer for Spark in the fall of 2022.
With more than 25 years’ end to end leadership experience in gene therapy, biotech, pharmaceutical and consumer products industries, Chris is an industry veteran with deep expertise in designing and operating supply chains in complex regulatory environments, manufacturing science and technology, technology transfer, quality, compliance, product strategy and P&L management.
Prior to Spark, Chris led teams at GlaxoSmithKline (GSK) focused on strategy, operations and planning, as well as GMP clinical manufacturing operations including process transfer and cell banking. Earlier in his career he held roles of increasing responsibility at Bristol-Myers Squibb (BMS) in process engineering, manufacturing and supply chain in Massachusetts, Indiana and Puerto Rico.
Beyond his role with Spark, Chris currently serves as Vice President of the Board at A Haven – a non-profit family grief center in Chester County, Pennsylvania. He received his M.S. in Industrial Management from the University of Southern Indiana and a B.S. in Chemical Engineering from Purdue University.